Dharam Kumbhani, Dominick J. Angiolillo, Jarett Berry, Tracy Wang

Dharam Kumbhani, MD, SM, MRCP, FACC, FAHA, FSCAI

Assistant Professor, Interventional Cardiology Department of Internal Medicine
UT Southwestern Medical Center
Dallas, TX

Back to top

Dominick J. Angiolillo, MD, PHD, FACC, FESC, FSCAI

Professor of Medicine with Tenure
Director, Cardiovascular Research
Program Director, Interventional Cardiology Fellowship
University of Florida College of Medicine
Jacksonville, Florida

Dr. Angiolillo graduated from the Catholic University of the Sacred Heart Medical School in Rome, Italy, where he completed training in Medicine and Cardiology. He subsequently pursued training in Interventional Cardiology at the Complutense University of Madrid in Spain. Ultimately, Dr. Angiolillo received his PhD in Cellular and Molecular Cardiology. After completing his training, Dr. Angiolillo joined the University of Florida College of Medicine-Jacksonville in 2004. Currently, Dr. Angiolillo is a Professor of Medicine with Tenure status. He is also the Director of Cardiovascular Research, Program Director, of the Interventional Cardiology Fellowship program, and Staff Cardiologist and Interventional Cardiologist at the University of Florida Health System. Dr. Angiolillo is triple Board Certified by the American Board of Internal Medicine (Internal Medicine, Cardiovascular Disease, Interventional Cardiology).

Much of Dr. Angiolillo’s professional career has been devoted to cardiovascular research in the field of interventional cardiology and acute coronary syndrome. His largest national and international recognition has been for his pivotal contributions in the field of thrombosis. In particular, Dr. Angiolillo has performed seminal studies on platelet function and modulation of antiplatelet drug response, including genetic studies, for which he has received numerous national and international academic recognitions. Amongst these he has received the 2013 Outstanding Achievement Award from the European Society of Cardiology and was most recently named to Thomson Reuters’ 2014 and 2015 list of The World’s Most Influential Scientific Minds. He has also been a key investigator in the clinical development of numerous novel antithrombotic agents, working along slide with drug regulating agencies in the United States (FDA) and Europe (EMA), towards approval of these drugs and product labeling updates. His success in obtaining extramural funding has allowed to develop one of the most active clinical research centers in the United States, as well as one of the leading centers for thrombosis research in the world.

Dr. Angiolillo has made major scientific contributions to many medical and cardiovascular journals, as well as textbooks of cardiovascular medicine. He has authored over 300 peer-reviewed articles with over 20,000 citations and an H-index of 77. He has authored over 30 book chapters, and he is the editor of his own textbook on antithrombotic medicine. Due to his major contributions to the field of antithrombotic therapy in patients with cardiovascular disease manifestations, Dr. Angiolillo has been invited to deliver numerous lectures across the globe. His international visibility has also allowed him to develop a very active post-doctoral research program attracting physicians and scientists from across the globe to train under his leadership. In addition to these responsibilities, Dr. Angiolillo has been a clinical mentor to numerous residents and fellows for which he has been recognized in multiple occasions with an Exemplary Teacher Award. His leadership role as an academic clinician scientist has allowed to him to nurture and promote career growth and development of many young trainees pursuing both academic and clinical careers in the United States and abroad.

Dr. Angiolillo is an active member of many cardiovascular societies in the Unites States and Europe. In addition, he is on the editorial board of numerous cardiovascular journals, some of which he also holds leadership roles. He is a scientific reviewer for many major journals and extramural funding agencies, including the National Institute of Health, and other federal funding agencies in several European countries.

Back to top

Jarett Berry, MD, MS, FAHA

Associate Professor of Medicine and Clinical Sciences
Dedman Family Scholar in Clinical Care
Division of Cardiology
University of Texas Southwestern Medical Center
Dallas, TX

Dr. Berry is a Dedman Family Scholar in Clinical Care and an Associate Professor of Medicine and an Associate Professor of Clinical Sciences at UT Southwestern in Dallas, TX. He completed his Medical Degree and Internal Medicine residency at UT Southwestern, and his Clinical Cardiology and research training at Northwestern University in Chicago, IL.

Dr. Berry’s clinical interests include both preventive cardiology and general cardiology where he serves as the Director of Cardiac Rehabilitation and an attending physician in the coronary care unit at Parkland Hospital. He has a nationally recognized research program as a cardiovascular epidemiologist with a particular focus on cardiovascular risk estimation across the lifespan. He has published more than 90 peer-reviewed original papers. He serves as an associate editor for Circulation. He also serves as one of the senior investigators in the Dallas Heart Study and one of the principal investigators of UT Southwestern’s Strategically Focused Research Network funded by the American Heart Association. Dr. Berry’s research has been funded by both the National Institutes of Health and the American Heart Association and his work has been recognized by numerous national awards. He is actively involved in leadership roles for the American Heart Association’s Council on Epidemiology and Prevention.

Back to top

Tracy Wang, MD, MHS, MSc

Associate Professor of Medicine in Cardiology
Assistant Dean of Continuing Medical Education
Director, Duke Center for Educational Excellence
Duke University
Durham, NC

Dr. Wang is an Associate Professor of Medicine (Cardiology) at Duke University in Durham, NC. An undergraduate of Yale University, she also holds an MSc Degree in Molecular Biochemistry/Biophysics from Yale University, a Medical Degree from Harvard Medical School, and a Master of Health Science Degree in Clinical Research from Duke University. After completing Internal Medicine residency training at Brigham and Women’s Hospital in Boston, MA, she came to Duke University for Cardiology fellowship training.

Since joining the faculty at Duke in 2008, Dr. Wang has conducted research related to quality of care and outcomes among patients with cardiovascular disease. She has been a leader in the development of several cardiovascular clinical trials and registries at the Duke Clinical Research Institute (DCRI) that have focused on comparative effectiveness and safety, health disparities, care quality assessment and quality improvement. Dr. Wang has published over 100 original manuscripts on these topics.

Dr. Wang has lectured widely on registry data, novel antiplatelet and anticoagulant therapies, and evidence-based therapy implementation among high-risk patients. Additionally, she has led performance improvement education initiatives in the areas of acute coronary syndrome and atrial fibrillation management. She has leadership roles within the American Heart Association and the American College of Cardiology, and serves on many other national committees and journal editorial boards.

Dr. Wang is the Director of the Duke Center for Educational Excellence and the Associate Director of the DCRI Fellowship Program. Dr. Wang remains a practicing noninvasive Cardiologist with both inpatient and outpatient responsibilities.

Dr. Wang has disclosed that she is a consultant for AstraZeneca and Lilly and receives grant/research support from AstraZeneca, Lilly, Bristol-Myers Squibb and Gilead.

Back to top